Irbecor Comp.

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbecor Comp., are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for systemic use. They are prescribed to lower elevated blood pressure in adult patients with hypertension. The combination exploits complementary mechanisms to achieve consistent blood pressure control and reduce cardiovascular risk.

GNH USA supplies Irbecor Comp. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Irbecor Comp. is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular outcomes. Essential hypertension: provides consistent blood pressure control in patients not adequately controlled by monotherapy. High blood pressure: assists in achieving target blood pressure levels as part of combination therapy.

Irbecor Comp. may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Increased urination: due to diuretic action. - Electrolyte imbalance: changes in potassium or sodium levels. - Fatigue: feeling of tiredness or reduced energy. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Hyperkalemia: elevated potassium that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: dangerously low blood pressure. - Allergic reaction: rash, itching, or anaphylaxis.

Before prescribing Irbecor Comp., clinicians should consider several precautionary measures to ensure patient safety.

- Monitor blood pressure: check regularly to avoid hypotension. - Assess electrolytes: especially potassium and sodium levels during therapy. - Evaluate renal function: test serum creatinine and eGFR before and during treatment. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in pregnancy unless clearly needed: limited safety data are available. - Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/hydrochlorothiazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: combined use may increase risk of renal dysfunction and hyperkalemia. - Potassium supplements or potassium‑sparing diuretics: can cause dangerous hyperkalemia. - Lithium: thiazide component may raise lithium levels, risking toxicity. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Cyclosporine: may increase serum concentrations of both agents.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may enhance blood pressure lowering, requiring dose adjustments. - Diuretics: additive diuretic effect can lead to electrolyte disturbances. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan levels. - Antidiabetic drugs: thiazide may affect glucose control. - Anticoagulants: thiazide may increase INR, necessitating monitoring.